<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01596283</url>
  </required_header>
  <id_info>
    <org_study_id>12-056</org_study_id>
    <nct_id>NCT01596283</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection</brief_title>
  <official_title>A Prospective Randomized Controlled Clinical Trial of Standard Compared to Goal-directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to help us learn what is the best amount of fluid to administer
      to patients during liver surgery. Patients will receive either an amount for this surgery
      based on weight, blood pressure, heart rate and urine output or an amount guided by a
      computerized system (FloTrac) that helps doctors know how much fluid each patient needs. The
      FloTrac calculates the amount of fluid patients needs on a minute-to-minute basis, based on
      real time information like blood pressure, pulse and the ability of the heart and blood
      vessels to maintain normal vital signs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Complications</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>The incidence of overall 30-day postoperative complications will be recorded. These are defined in the MSKCC Adverse Events Program and organized by categories reflecting organ systems and further subdivided into specific complications within those and graded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low Cardiac Output Time</measure>
    <time_frame>Up to the first 24 postoperative hours</time_frame>
    <description>Assess the impact of GDT compared to standard fluid therapy on the total time patients experience low cardiac output perioperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Volume of Fluid Used Perioperatively</measure>
    <time_frame>Up to the first 72 hours postoperatively</time_frame>
    <description>Assess the impact of GDT compared to standard fluid therapy on the total volume of fluid given intraoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Volume of Fluid Used Postoperatively</measure>
    <time_frame>Postoperatively for the total admission time, up to 8 days</time_frame>
    <description>Postoperative fluid volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Length of Stay</measure>
    <time_frame>Postoperatively for the total admission time, up to 8 days</time_frame>
    <description>Assess the impact of GDT compared to standard fluid therapy on net fluid balance for the total admission time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Standard fluid management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Goal directed fluid therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard fluid management</intervention_name>
    <description>The patient will receive standard fluid management</description>
    <arm_group_label>Standard fluid management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Goal directed fluid therapy with the Edwards EV1000 system</intervention_name>
    <description>This arm will have fluid therapy guided by the Edwards EV1000 system.</description>
    <arm_group_label>Goal directed fluid therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (18 years old or greater) who are able to provide informed consent.

          -  Patients who undergo an open, elective liver resection. Including those initially
             approached laparoscopically but converted to an open resection and those undergoing
             additional procedures.

        Exclusion Criteria:

          -  Active coronary disease.

          -  Patients with a history of coronary disease will be eligible if they have had a
             cardiac stress study showing no reversible ischemia and normal LV function within 3
             months of operation.

          -  Active symptomatic cerebrovascular disease.

          -  Active congestive heart failure and ejection fraction &lt;35%.

          -  Active severe restrictive or obstructive pulmonary disease and resting SpO2 &lt;90%.

          -  Active renal dysfunction (Cr &gt;1.8)

          -  Abnormal coagulation parameters (INR &gt; 1.8 not on Coumadin, or platelet count &lt;
             100,000 per mcL)

          -  Presence of active infection including HIV

          -  Patients with active atrial fibrillation or flutter.

          -  Preoperative hypoalbuminemia (Albumin &lt; 2g/dl).

          -  Female patients who are pregnant (female patients of child-bearing potential must have
             a negative serum pregnancy test â‰¤ 14 days prior to surgery or 15 to 30 days prior to
             surgery with a negative urine pregnancy test the morning of surgery).

          -  Presence of ascites.

          -  BMI &gt; 45 or &lt;17
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Fischer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <results_first_submitted>May 2, 2017</results_first_submitted>
  <results_first_submitted_qc>September 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2017</results_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Perioperative Fluid Management</keyword>
  <keyword>liver resection</keyword>
  <keyword>12-056</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Goal-directed Therapy (GDT) After Liver Resection</title>
          <description>Patients who undergo an open, elective liver resection, Including those initially approached laparoscopically but converted to an open resection and those undergoing additional procedures. Goal-directed therapy (GDT) embodies a number of physiologic strategies to achieve an ideal fluid balance and avoid the consequences of over- or under-resuscitation.</description>
        </group>
        <group group_id="P2">
          <title>Standard Perioperative Resuscitation After Liver Resection</title>
          <description>Patients who undergo an open, elective liver resection, Including those initially approached laparoscopically but converted to an open resection and those undergoing additional procedures.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Goal-directed Therapy</title>
        </group>
        <group group_id="B2">
          <title>Standard Perioperative Resuscitation</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="13"/>
                    <measurement group_id="B2" value="58" spread="14"/>
                    <measurement group_id="B3" value="57" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Complications</title>
        <description>The incidence of overall 30-day postoperative complications will be recorded. These are defined in the MSKCC Adverse Events Program and organized by categories reflecting organ systems and further subdivided into specific complications within those and graded.</description>
        <time_frame>30 days post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Fluid Management</title>
            <description>Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
Standard fluid management: The patient will receive standard fluid management</description>
          </group>
          <group group_id="O2">
            <title>Goal Directed Fluid Therapy</title>
            <description>Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
Goal directed fluid therapy with the Edwards EV1000 system: This arm will have fluid therapy guided by the Edwards EV1000 system.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Complications</title>
          <description>The incidence of overall 30-day postoperative complications will be recorded. These are defined in the MSKCC Adverse Events Program and organized by categories reflecting organ systems and further subdivided into specific complications within those and graded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>30-day survival</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>30-day overall morbidity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Cardiac Output Time</title>
        <description>Assess the impact of GDT compared to standard fluid therapy on the total time patients experience low cardiac output perioperatively</description>
        <time_frame>Up to the first 24 postoperative hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Fluid Management</title>
            <description>Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
Standard fluid management: The patient will receive standard fluid management</description>
          </group>
          <group group_id="O2">
            <title>Goal Directed Fluid Therapy</title>
            <description>Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
Goal directed fluid therapy with the Edwards EV1000 system: This arm will have fluid therapy guided by the Edwards EV1000 system.</description>
          </group>
        </group_list>
        <measure>
          <title>Low Cardiac Output Time</title>
          <description>Assess the impact of GDT compared to standard fluid therapy on the total time patients experience low cardiac output perioperatively</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="113"/>
                    <measurement group_id="O2" value="12" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Volume of Fluid Used Perioperatively</title>
        <description>Assess the impact of GDT compared to standard fluid therapy on the total volume of fluid given intraoperatively</description>
        <time_frame>Up to the first 72 hours postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Goal-directed Therapy (GDT) After Liver Resection</title>
            <description>Patients who undergo an open, elective liver resection, Including those initially approached laparoscopically but converted to an open resection and those undergoing additional procedures. Goal-directed therapy (GDT) embodies a number of physiologic strategies to achieve an ideal fluid balance and avoid the consequences of over- or under-resuscitation.</description>
          </group>
          <group group_id="O2">
            <title>Standard Perioperative Resuscitation After Liver Resection</title>
            <description>Patients who undergo an open, elective liver resection, Including those initially approached laparoscopically but converted to an open resection and those undergoing additional procedures.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Volume of Fluid Used Perioperatively</title>
          <description>Assess the impact of GDT compared to standard fluid therapy on the total volume of fluid given intraoperatively</description>
          <units>liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.1"/>
                    <measurement group_id="O2" value="2.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Volume of Fluid Used Postoperatively</title>
        <description>Postoperative fluid volume</description>
        <time_frame>Postoperatively for the total admission time, up to 8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Goal-directed Therapy (GDT) After Liver Resection</title>
            <description>Patients who undergo an open, elective liver resection, Including those initially approached laparoscopically but converted to an open resection and those undergoing additional procedures. Goal-directed therapy (GDT) embodies a number of physiologic strategies to achieve an ideal fluid balance and avoid the consequences of over- or under-resuscitation.</description>
          </group>
          <group group_id="O2">
            <title>Standard Perioperative Resuscitation After Liver Resection</title>
            <description>Patients who undergo an open, elective liver resection, Including those initially approached laparoscopically but converted to an open resection and those undergoing additional procedures.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Volume of Fluid Used Postoperatively</title>
          <description>Postoperative fluid volume</description>
          <units>liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.6"/>
                    <measurement group_id="O2" value="1.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Length of Stay</title>
        <description>Assess the impact of GDT compared to standard fluid therapy on net fluid balance for the total admission time</description>
        <time_frame>Postoperatively for the total admission time, up to 8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Goal-directed Therapy (GDT) After Liver Resection</title>
            <description>Patients who undergo an open, elective liver resection, Including those initially approached laparoscopically but converted to an open resection and those undergoing additional procedures. Goal-directed therapy (GDT) embodies a number of physiologic strategies to achieve an ideal fluid balance and avoid the consequences of over- or under-resuscitation.</description>
          </group>
          <group group_id="O2">
            <title>Standard Perioperative Resuscitation After Liver Resection</title>
            <description>Patients who undergo an open, elective liver resection, Including those initially approached laparoscopically but converted to an open resection and those undergoing additional procedures.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Length of Stay</title>
          <description>Assess the impact of GDT compared to standard fluid therapy on net fluid balance for the total admission time</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="6" upper_limit="8"/>
                    <measurement group_id="O2" value="6" lower_limit="5" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Fluid Management</title>
          <description>Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
Standard fluid management: The patient will receive standard fluid management</description>
        </group>
        <group group_id="E2">
          <title>Goal Directed Fluid Therapy</title>
          <description>Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
Goal directed fluid therapy with the Edwards EV1000 system: This arm will have fluid therapy guided by the Edwards EV1000 system.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Biliary anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Biloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Intra-abdominal infection or abscess</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Non-infected intra-abdominal/intra-thoracic fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic Event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Bowel perforation, necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Ileus, paralytic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Biliary anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Biloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hepatic arterial infusion pump dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Intra-abdominal infection of abscess</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Foreign body infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bile duct injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Splenic injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Wound breakdown</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fascial dehiscence or evisceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Non-infeccted intra-abdominal/intra-thoracic fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Apnea or Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Vascular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mary Fischer MD</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>212-639-6745</phone>
      <email>fischerm@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

